Related Experiment Videos
Epidemiological, immunogenetic and immunotherapeutic aspects of unexplained recurrent miscarriage
1Department of Clinical Immunology, Aalborg Hospital.
Danish Medical Bulletin
|October 6, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Angiogenic factors and the lectin pathway of complement in women with secondary recurrent pregnancy loss.
Journal of reproductive immunology·2024
Maternal carriage of H-Y restricting HLA class II alleles is a negative prognostic factor for women with recurrent pregnancy loss after birth of a boy.
Journal of reproductive immunology·2023
Seminal plasma metabolomics profiles following long (4-7 days) and short (2 h) sexual abstinence periods.
European journal of obstetrics, gynecology, and reproductive biology·2021
HLA-DRB1 polymorphism in recurrent pregnancy loss: New evidence for an association to HLA-DRB1*07.
Journal of reproductive immunology·2021
Chance of live birth in the first pregnancy after referral among patients with recurrent pregnancy loss is not influenced by their relatives' reproductive history.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2020
Pain and convalescence following laparoscopic ventral hernia repair.
Danish medical bulletin·2011
Communication with patients and colleagues.
Danish medical bulletin·2011
Short convalescence and minimal pain after out-patient Bascom's pit-pick operation.
Danish medical bulletin·2011
Association Between UGT1A9 rs13418420 Polymorphism and Propofol Induction Characteristics in Chinese Female Patients Undergoing Brief Gynecological Procedures.
Pharmacogenomics and personalized medicine·2026
Clinical pearls and pitfalls in inborn errors of immunity: An expert-derived framework for diagnostic pattern recognition.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.
Annals of clinical and translational neurology·2026